canertinib has been researched along with topotecan in 2 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 2,392 | 626 | 792 |
| Protein | Taxonomy | canertinib (IC50) | topotecan (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY | 1 |
2 other study(ies) available for canertinib and topotecan
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |